<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74943">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02129998</url>
  </required_header>
  <id_info>
    <org_study_id>Progesterone/PIF_Skive</org_study_id>
    <nct_id>NCT02129998</nct_id>
  </id_info>
  <brief_title>The Role of Progesterone and PIF for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology</brief_title>
  <official_title>The Role of Luteal Progesterone and Preimplantation Factor (PIF) for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regionshospitalet Viborg, Skive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioIncept LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Regionshospitalet Viborg, Skive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to achieve a more profound understanding of the endocrine
      alteration in luteal progesterone level after gonadotrophin stimulated IVF/ICSI cycles and
      to explore the optimal progesterone level needed for securing implantation and development
      of early pregnancy.

      The second part of the project will determine the value of Preimplantation Factor (PIF)
      measurement in embryo culture medium as a possible tool for improved embryo selection and
      the use of PIF as an early pregnancy serum marker for healthy implantation and embryo
      development.

      IVF: In vitro fertilisation, ICSI: Intracytoplasmic sperm injection.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>On-going pregnancy rate</measure>
    <time_frame>10th week of gestation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantation rate</measure>
    <time_frame>7th week of gestation</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Standard IVF/ICSI treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IVF/ICSI treatment</intervention_name>
    <arm_group_label>Standard IVF/ICSI treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, Embryo culture media
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing IVF/ICSI treatment at 4 Danish Fertility Centres.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -All women undergoing IVF/ICSI treatment at the participating clinics in either antagonist
        protocol or long agonist protocol will be offered participation.

        Exclusion Criteria:

        -Prior participation in the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Fertility Clinic Skive</name>
      <address>
        <city>Skive</city>
        <zip>7800</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 18, 2016</lastchanged_date>
  <firstreceived_date>May 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Regionshospitalet Viborg, Skive</investigator_affiliation>
    <investigator_full_name>Peter Humaidan</investigator_full_name>
    <investigator_title>Professor, DMSc</investigator_title>
  </responsible_party>
  <keyword>Infertility</keyword>
  <keyword>IVF/ICSI</keyword>
  <keyword>Progesterone</keyword>
  <keyword>Preimplantation Factor (PIF)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
